Document is current
Any future updates will be listed below
-
Authors
Boyiadzis, Michael M
Aksentijevich, Ivan
Arber, Daniel A
Barrett, John
Brentjens, Renier J
Brufsky, Jill
Cortes, Jorge
De Lima, Marcos
Forman, Stephen J
Fuchs, Ephraim J
Fukas, Linda J
Gore, Steven D
Litzow, Mark R
Miller, Jeffrey S
Pagel, John M
Waller, Edmund K
Tallman, Martin S
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02152956 at ClinicalTrials.govnct02674763 at ClinicalTrials.govDocuments that mention this clinical trial
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct02013167 at ClinicalTrials.govDocuments that mention this clinical trial
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct02000427 at ClinicalTrials.govDocuments that mention this clinical trial
Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia
https://doi.org/10.1080/16078454.2022.2074704
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct01471782 at ClinicalTrials.govDocuments that mention this clinical trial
Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia
https://doi.org/10.1080/16078454.2022.2074704
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct01207388 at ClinicalTrials.govDocuments that mention this clinical trial
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct03214666 at ClinicalTrials.govDocuments that mention this clinical trial
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct02665065 at ClinicalTrials.govDocuments that mention this clinical trial
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
444 GTB-3550 tri-specific killer engager TriKE™ drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients
https://doi.org/10.1136/jitc-2021-sitc2021.444
nct01830777 at ClinicalTrials.govDocuments that mention this clinical trial
Randomized Phase III SIERRA Trial of <sup>131</sup> I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
https://doi.org/10.1200/jco.23.02018
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct04033302 at ClinicalTrials.govDocuments that mention this clinical trial
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct03904069 at ClinicalTrials.govDocuments that mention this clinical trial
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct04023071 at ClinicalTrials.govDocuments that mention this clinical trial
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
nct03876769 at ClinicalTrials.govDocuments that mention this clinical trial
365 Oxygen levels found in bone marrow (5%) provide an optimal niche for the differentiation of induced-pluripotent stem cell-derived NK cells for the treatment of AML
https://doi.org/10.1136/jitc-2023-sitc2023.0365
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
https://doi.org/10.1136/jitc-2022-004693
Documents that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810
- License Information
